Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher G Bunick

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
Journal of Drugs in Dermatology : JDD|July 8, 2025
Treating Chronic Hand Eczema with Upadacitinib: Insights from Clinical Trials and Real-World ExperienceOmar Alani, Lara Shqair, Walter J Liszewski, et al.
Clinical and Experimental Dermatology|February 16, 2023
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosisDedee F Murrell, Joyce M C Teng, Scott Guenthner, et al.
Clinical and Experimental Dermatology|March 17, 2023
Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL studyChristopher G Bunick, Joyce M C Teng, Scott Guenthner, et al.
Dermatology and Therapy|May 24, 2026
Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck RegionKilian Eyerich, Pedro Mendes-Bastos, Gregor Holzer, et al.
Scientific Reports|July 2, 2025
Surface keratin 1, a tumor-selective peptide target in human triple-negative breast cancerShih-Jing Yao, Farideh Amirrad, Elmira Ziaei, et al.
Journal of Drugs in Dermatology : JDD|October 3, 2024
Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 AnalysisEdward Ted Lain, Neal Bhatia, Leon Kircik, et al.
The Journal of Investigative Dermatology|September 7, 2025
Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and PolicyJoshua Burshtein, Christopher G Bunick, Ruth Ann Vleugels, et al.
Dermatology and Therapy|July 2, 2026
Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque PsoriasisJeffrey Crowley, Eingun James Song, Linda Stein-Gold, et al.
The Journal of Investigative Dermatology|May 29, 2025
Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 InhibitorShailly Mehrotra, Yasuyo Sano, Petro Halkowycz, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2025
Fluoroquinolones for Dermatologists: A Practical Guide to Clinical Use and Risk ManagementSamer Wahood, Omar Alani, Iyla Draw, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
Journal of Drugs in Dermatology : JDD|July 8, 2025
Treating Chronic Hand Eczema with Upadacitinib: Insights from Clinical Trials and Real-World ExperienceOmar Alani, Lara Shqair, Walter J Liszewski, et al.
Clinical and Experimental Dermatology|February 16, 2023
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosisDedee F Murrell, Joyce M C Teng, Scott Guenthner, et al.
Clinical and Experimental Dermatology|March 17, 2023
Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL studyChristopher G Bunick, Joyce M C Teng, Scott Guenthner, et al.
Dermatology and Therapy|May 24, 2026
Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck RegionKilian Eyerich, Pedro Mendes-Bastos, Gregor Holzer, et al.
Scientific Reports|July 2, 2025
Surface keratin 1, a tumor-selective peptide target in human triple-negative breast cancerShih-Jing Yao, Farideh Amirrad, Elmira Ziaei, et al.
Journal of Drugs in Dermatology : JDD|October 3, 2024
Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 AnalysisEdward Ted Lain, Neal Bhatia, Leon Kircik, et al.
The Journal of Investigative Dermatology|September 7, 2025
Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and PolicyJoshua Burshtein, Christopher G Bunick, Ruth Ann Vleugels, et al.
Dermatology and Therapy|July 2, 2026
Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque PsoriasisJeffrey Crowley, Eingun James Song, Linda Stein-Gold, et al.
The Journal of Investigative Dermatology|May 29, 2025
Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 InhibitorShailly Mehrotra, Yasuyo Sano, Petro Halkowycz, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2025
Fluoroquinolones for Dermatologists: A Practical Guide to Clinical Use and Risk ManagementSamer Wahood, Omar Alani, Iyla Draw, et al.
Pageof 16